What Regeneron's 8-K filings say: 7 filings, latest Oct 30, 2026
Regeneron filed its latest 8-K with the SEC on Oct 30, 2026. It discusses major contract win, pricing pressure and product launch.
Public (REGN)Biotechnology Research10,000+ employeesregeneron.comLinkedIn
Get Regeneron's live signals in Claude or ChatGPT, or by API
What changed at Regeneron this week? Use Autobound signals for regeneron.com.- Filed
- Oct 30, 2026
- Filings
- 7
- Signals
- 20
Source: Autobound Signal API · 94 signals tracked for Regeneron · updated
8-K · latest 10
What Regeneron's 8-K filings say
- SEC EDGAR
8-K
Filed · 3 signals
Regeneron Secures BARDA Agreement to Supply Inmazeb for Ebola Preparedness Through 2031
Regeneron announced an agreement with BARDA to provide additional supply of Inmazeb for U.S.
EYLEA HD net selling price declines despite higher sales volumes driving demand
Regeneron reported that EYLEA HD U.S. net product sales growth was partly offset by a lower net selling price.
62%
increase in EYLEA HD U.S. net product sales
FDA Approves Pasatru for Treatment of Fibrodysplasia Ossificans Progressiva
In August 2026, the FDA approved Pasatru (garetosmab) to reduce new heterotopic ossification lesions and flare-ups in adults with FOP.
- SEC EDGAR
8-K
Filed · 5 signals
Regeneron secures $1B upfront in expanded Sanofi collaboration for new antibody development.
Regeneron is expanding its partnership with Sanofi to co-develop and co-commercialize four new antibodies, with potential for an additional $7B in milestones.
$1B
Upfront payment from Sanofi for co-development and co-commercialization of four new antibodies.
antibodiesbispecific antibodyNanobody VHH therapySanofi
This massive, multi-year development partnership will generate enormous volumes of clinical trial data across four new products.
$1B
Upfront payment from Sanofi for a co-development and co-commercialization agreement for four new antibody products.
Nanobody® VHH therapy
The settlement resolves a dispute concerning Sanofi's obligation to provide full access to commercialization data, highlighting a critical need for robust information sharing and auditing platforms, especially as their collaboration expands significantly.
Regeneron to take ~$22M IPR&D charge in Q3 2026, reducing EPS by ~$0.18.
The company will record an acquired in-process research and development (IPR&D) charge of approximately $22 million, which is expected to directly reduce reported GAAP and non-GAAP profitability for the third quarter of 2026.
$22M
Acquired in-process research and development (IPR&D) charge on a pre-tax basis.
- SEC EDGAR
8-K
Filed · 2 signals
Regeneron mandates formal CEO and CSO succession plans to be completed within 5 years.
As a condition of new 10-year incentive awards, the co-founder CEO and CSO must formalize succession plans by 2031.
- SEC EDGAR
8-K
Filed · 3 signals
Regeneron announces $127M charge for acquiring in-process R&D via licensing/collaboration deals.
Regeneron is investing $127M in external innovation through collaboration and licensing deals, creating a need to integrate and develop these new R&D assets.
$127M
Acquired in-process research and development (IPR&D) charge related to collaboration and licensing agreements
Regeneron to take a $127M charge in Q2 2026, negatively impacting earnings per share by ~$1.00.
The company is recording a significant $127 million pre-tax charge for acquired in-process R&D from collaboration and licensing deals.
$127M
Acquired in-process research and development (IPR&D) pre-tax charge
Earlier 8-K filings
Showing 10 of 20 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Regeneron with the Signal API
One POST /v1/companies/enrich call with regeneron.com returns Regeneron 8-K signals (sec-8k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"regeneron.com","signal_types":["sec-8k"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 8-K Filings records, as a CSV.
Same industry
8-K at related companies
Questions about Regeneron 8-K
When did Regeneron file its latest 8-K?
What did Regeneron disclose in its latest 8-K?
Where can I read Regeneron's 8-K filing?
Page updated , the date of the newest row on this page.
Source. Current reports (Form 8-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .